Clinical Trials
39 trialsIGNYTE-ESO
USWM, LLC (dba US WorldMeds)
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
HESTIA
Baylor College of Medicine
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
ACCESS
Center for International Blood and Marrow Transplant Research
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
SELECT-CAR-NK
Essen Biotech
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Institutes of Health Clinical Center (CC)
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
FIRCE-1
CARGO Therapeutics
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
Peking University
ACTolog
Immatics US, Inc.
SCRIPT-AML
Vastra Gotaland Region
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Adaptimmune
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Adaptimmune
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Adaptimmune
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Dana-Farber Cancer Institute
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers
Gilead Sciences
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
NY-ESO-1
GlaxoSmithKline
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
Memorial Sloan Kettering Cancer Center
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
Memorial Sloan Kettering Cancer Center
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
University of Utah
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
RICE
University Hospital, Clermont-Ferrand